-
Tirzepatide With Glycine: Ask About the Formulation and the Longer-Term Plan
Understand tirzepatide/glycine formulation questions, why maintenance-trial findings do not validate an add-on, and what a longer-term…
-
Tirzepatide With B12: Reading Weight-Loss and Energy Claims Separately
Explore tirzepatide-with-B12 claims, distinguish clinical trial evidence from vitamin add-on assumptions, and prepare practical treatment questions.
-
Semaglutide With Glycine: Formulation, Concentration, and the Questions to Ask
Learn what a semaglutide/glycine label does and does not establish, why concentration differs from prescribed dose,…
-
Semaglutide With B12: What Does the Added Vitamin Actually Establish?
Understand semaglutide-with-B12 claims, why the original semaglutide trials do not validate an added vitamin, and what…
-
CJC-1295, Ipamorelin, and Sermorelin: Does a Triple Blend Have Triple Evidence?
Evaluate a CJC-1295/ipamorelin/sermorelin formulation by checking identity, combination evidence, intended outcomes, and a clear clinical rationale.
-
Reusable Injection Pens: Verify the Device, Cartridge, and Instructions Together
A practical checklist for a reusable injection pen: exact model, compatible cartridges, dose display, training, storage…
-
Ondansetron and Nausea: Relief Should Not Replace Finding the Cause
Understand ondansetron’s role in nausea care, why ongoing symptoms need assessment, and what to discuss if…
-
Tesofensine for Weight Loss: Read the Trial—and the Publication Notice
A careful guide to tesofensine weight-loss evidence, including an expression of concern attached to a widely…
-
SLU-PP-332 With BAM15: Why Two Experimental Mechanisms Do Not Make a Proven Capsule
Separate SLU-PP-332 and BAM15 preclinical findings from claims for a combined capsule, including route, human evidence,…
-
SLU-PP-332: What “Exercise Mimetic” Means in Mouse Research
Understand SLU-PP-332 exercise-mimetic research, its experimental models, and why the findings do not establish a capsule…